Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Imatinib Stories

2008-12-04 00:25:00

- Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH - Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can damage key organs - New long-term data from major independent breast cancer trial at SABCS to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen - Multiple Zometa studies at SABCS to...

2008-11-12 12:00:07

CytRx, a biopharmaceutical company, has announced that INNO-406, the company's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with chronic myeloid leukemia. INNO-406 is being evaluated for the treatment of patients with chronic myeloid leukemia (CML) and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+) and are intolerant of or resistant to imatinib and second line tyrosine...

2008-11-11 09:00:08

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML). INNO-406 is being evaluated for the treatment of patients with CML and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+)...

2008-10-30 06:00:44

GPC Biotech has reported preclinical data on RGB-286638, the company's multi-targeted protein kinase inhibitor, that supported the potential utility of RGB-286638 against some hematological malignancies. The data demonstrated that the RGB-286638 small molecule has potent activity against chronic myeloid leukemia (CML) in in vivo models that are resistant to imatinib (Gleevec) and to dasatinib (Sprycel), the current standards of care for treating this form of cancer. Additionally,...

2008-10-29 15:00:27

Oregon Health & Science University today announced that Philip H. and Penny Knight have pledged to give $100 million to the OHSU Cancer Institute. The Nike founder's gift - the largest in the history of OHSU - represents a critical step toward achieving the cancer institute's ambitious goal to make Oregon's cancer death rate the lowest in the nation. In recognition of the transformational impact the donors' generosity will have on the treatment of cancer, OHSU will rename its cancer...

2008-10-27 06:00:23

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578). The data presented demonstrate that the...

2008-10-16 09:00:42

Exelixis, Inc. (Nasdaq:EXEL) announced today that it will present 15 posters on the company's investigational compounds at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer Therapeutics," which will be held October 21-October 24 in Geneva, Switzerland. The titles, schedules, and locations for the poster presentations are provided below. Note that...

2008-10-08 09:00:12

EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib mesylate provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in...

2008-09-11 09:00:48

According to a new study by Cutting Edge Information, tyrosine kinase inhibitors may have five oncology drugs with annual sales over $1 billion by 2013. This list of blockbuster oncology drugs includes Novartis' Gleevec. Annual sales of Gleevec are projected to steadily grow to $4.6 billion dollars in 2012, making it a top five oncology drug. There are four other approved tyrosine kinase inhibitors that are estimated to surpass $1 billion in annual sales by 2013, one of which is Pfizer's...

2008-08-27 09:00:23

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- Novartis announced today that Gleevec(R) (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST). FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review timing from ten to six months(1)....